In vitro method for predicting the biocompatibility of medical implants

June 15, 2017, Asociacion RUVID

Researchers at the Universitat Jaume I (UJI), the University of the Basque Country (UPV-EHU) and the Centre for Cooperative Research in Biosciences (CIC bioGUNE) have patented a new in vitro method for predicting the biocompatibility of materials to be used in the manufacture of medical implants, such as joint and dental prostheses, valves and stents.

The patent is based on the detection of a group of proteins linked to the inflammatory reaction. In fact, researchers have identified a profile of protein markers, related to the immune response, that can be analysed in an isolated biological sample in vitro, and whose presence above a reference level is indicative of non-biocompatibility in vivo. "This methodology," explains the researcher Nuno Araújo, "will enable us to face the experiment in vivo with more security in the future, and to reduce the number of animals involved, while reducing time and costs."

The invention consists in an accelerated test of the biocompatibility of materials that makes it possible to discard those with poorer prospects of success during the in vitro phase, thus avoiding costly investments in unnecessary in vivo studies and facilitating a faster transfer of the to the clinical stage. It accelerates and significantly reduces the development of new implant materials and reduces the number of animals used for experimentation.

This methodology involves a robust correlation between the protein profile obtained in the in vitro tests and that acquired by means of in vivo trials, which are, by definition, more reliable. Thus, through the in vitro/in vivo correlation, determination and quantification of such markers in in vitro samples predicts the biocompatibility of biomaterials-implants, joint and dental prostheses or catheters, according to main researcher Julio Suay.

The technology is useful for the sectors of manufacturers of medical prostheses and for the producers of biomaterials, as well as for research groups of R & D centres that carry out in vitro and in vivo tests applied to the development of new materials. In the healthcare sector, it is particularly useful for patients who need an implant. In fact, with a simple blood test, detailed information could be obtained about whether the patient is likely to suffer complications in .

Explore further: Researchers increase the success rate of tooth implants

More information: Francisco Romero-Esparver et al. Proteome analysis of human serum proteins adsorbed onto different titanium surfaces used in dental implants, Biofouling (2016). DOI: 10.1080/08927014.2016.1259414

Related Stories

Researchers increase the success rate of tooth implants

April 29, 2013
Elderly or people with osteoporosis, smokers, diabetics or people who have had cancer are sometimes not eligible to receive dental implants as their bones are unable to correctly integrate the new prostheses which replace ...

Scientists increase the success rate of tooth implants

January 21, 2013
Elderly or people with osteoporosis, smokers, diabetics or people who have had cancer are sometimes not eligible to receive dental implants as their bones are unable to correctly integrate the new prostheses which replace ...

A novel animal model for analysing human natural killer cell functions in vivo

March 27, 2017
Natural killer (NK) cells which belong in innate immunity, play an important role for defense against invading pathogens and microbes. NK cells make up around 5-20% of the white blood cells circulating in the bloodstream ...

Stem cells may significantly improve tendon healing by regulating inflammation

May 23, 2017
New research published online in The FASEB Journal suggests that tendon stem (TSCs) may be able to significantly improve tendon healing by regulating inflammation, which contributes to scar-like tendon healing and chronic ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.